Cargando…

Clinical role of brexpiprazole in depression and schizophrenia

Brexpiprazole, a serotonin–dopamine activity modulator, is the second D(2) partial agonist to come to market and has been approved for the treatment of schizophrenia and as an adjunctive treatment in major depressive disorder. With less intrinsic activity than aripiprazole at the D(2) receptor and h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parikh, Nishant B, Robinson, Diana M, Clayton, Anita H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354524/ https://www.ncbi.nlm.nih.gov/pubmed/28331332 http://dx.doi.org/10.2147/TCRM.S94060

Ejemplares similares

Brexpiprazole—Pharmacologic Properties and Use in Schizophrenia and Mood Disorders
por: Siwek, Marcin, et al.
Publicado: (2023)

Spotlight on brexpiprazole and its potential in the treatment of schizophrenia and as adjunctive therapy for the treatment of major depression
por: Bruijnzeel, Dawn, et al.
Publicado: (2016)

Brexpiprazole: A review of a new treatment option for schizophrenia and major depressive disorder
por: Diefenderfer, Lauren A., et al.
Publicado: (2018)

Continuation rate for asenapine and brexpiprazole treatment in patients with schizophrenia
por: Inoue, Yuichi, et al.
Publicado: (2021)

Brexpiprazole for the Treatment of Schizophrenia in Adults: An Overview of Its Clinical Efficacy and Safety and a Psychiatrist’s Perspective
por: Watanabe, Yoshinori, et al.
Publicado: (2020)

Effect of Brexpiprazole on Prolactin and Sexual Functioning: An Analysis of Short- and Long-Term Study Data in Major Depressive Disorder
por: Clayton, Anita H., et al.
Publicado: (2020)

Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
por: Ward, Kristen, et al.
Publicado: (2019)

The effect of brexpiprazole in adult outpatients with early-episode schizophrenia: an exploratory study
por: Malla, Ashok, et al.
Publicado: (2016)

Effect of Brexpiprazole on Prolactin: An Analysis of Short- and Long-Term Studies in Schizophrenia
por: Ivkovic, Jelena, et al.
Publicado: (2019)

Subjective assessment of brexpiprazole in patients with schizophrenia: a prospective observational study
por: Yokoi, Rina, et al.
Publicado: (2023)

Pharmacokinetics and Safety of Brexpiprazole Following Multiple‐Dose Administration to Japanese Patients With Schizophrenia
por: Ishigooka, Jun, et al.
Publicado: (2017)

O7.5. LONG-TERM SAFETY AND TOLERABILITY OF BREXPIPRAZOLE IN PATIENTS WITH SCHIZOPHRENIA
por: Hakala, Mika, et al.
Publicado: (2018)

Analysis of the effect of brexpiprazole on sleep architecture in patients with schizophrenia: A preliminary study
por: Arai, Yusuke, et al.
Publicado: (2023)

Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USA
por: Aigbogun, Myrlene S, et al.
Publicado: (2018)

M191. EFFECT OF BREXPIPRAZOLE ON ENGAGEMENT IN PATIENTS WITH SCHIZOPHRENIA: POST-HOC ANALYSIS OF THREE STUDIES
por: Ismail, Zahinoor, et al.
Publicado: (2020)

Impressive Response with Brexpiprazole in Ekbom’s syndrome
por: Hsiao, J., et al.
Publicado: (2022)

Clozapine-Treatment-Resistant Schizophrenia Successfully Managed with Brexpiprazole Combination Therapy: Two Case Reports
por: Orsolini, L., et al.
Publicado: (2022)

Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study
por: Davis, Lori L., et al.
Publicado: (2016)

Efficacy and Safety of Low-Dose Brexpiprazole for Acute Schizophrenia: Meta-Analysis of Randomized Placebo-Controlled Trials
por: Zhao, Mingjun, et al.
Publicado: (2022)

Effects of adjunctive brexpiprazole on sleep-wake and circadian parameters in youth with depressive disorders: study protocol for a clinical trial
por: Carpenter, Joanne S, et al.
Publicado: (2022)

Newer antipsychotics: Brexpiprazole, cariprazine, and lumateperone: A pledge or another unkept promise?
por: Barman, Rajdip, et al.
Publicado: (2021)

Brexpiprazole for the Treatment of Agitation in Alzheimer Dementia: A Randomized Clinical Trial
por: Lee, Daniel, et al.
Publicado: (2023)

A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia
por: Forbes, Andy, et al.
Publicado: (2018)

PM384. The effect of brexpiprazole (OPC-34712) versus aripiprazole in adult patients with acute schizophrenia: an exploratory study
Publicado: (2016)

Effects of Brexpiprazole Across Symptom Domains in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies
por: Marder, Stephen R, et al.
Publicado: (2021)

PM421. Efficacy and safety of brexpiprazole (OPC-34712) in acute schizophrenia: a pooled analysis of two pivotal studies
por: Skuban, Aleksandar, et al.
Publicado: (2016)

Efficacy of Brexpiprazole as Adjunctive Treatment in Major Depressive Disorder With Irritability: Post Hoc Analysis of 2 Pivotal Clinical Studies
por: Fava, Maurizio, et al.
Publicado: (2017)

The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies
por: Weiss, Catherine, et al.
Publicado: (2018)

New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer’s disease: focus on brexpiprazole and pimavanserin
por: Caraci, Filippo, et al.
Publicado: (2020)

Long-Term Efficacy and Safety of Brexpiprazole in Elderly Japanese Patients with Schizophrenia: A Subgroup Analysis of an Open-Label Study
por: Inada, Ken, et al.
Publicado: (2020)

Efficacy and safety of brexpiprazole in patients with schizophrenia presenting with severe symptoms: Post-hoc analysis of short- and long-term studies
por: Meade, Nicole, et al.
Publicado: (2020)

Effect of Switching to Brexpiprazole on Plasma Homovanillic Acid Levels and Antipsychotic-Related Side Effects in Patients with Schizophrenia or Schizoaffective Disorder
por: Ichinose, Mizue, et al.
Publicado: (2021)

Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study
por: Fleischhacker, W. Wolfgang, et al.
Publicado: (2016)

Antidepressant effects of combination of brexpiprazole and fluoxetine on depression-like behavior and dendritic changes in mice after inflammation
por: Ma, Min, et al.
Publicado: (2016)

Real-World Economic Outcomes of Brexpiprazole and Extended-Release Quetiapine Adjunctive Use in Major Depressive Disorder
por: Seetasith, Arpamas, et al.
Publicado: (2019)

Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post‐hoc analysis of a long‐term open‐label study
por: Ishigooka, Jun, et al.
Publicado: (2021)

Treatment Discontinuation Among Patients with Schizophrenia Treated with Brexpiprazole and Other Oral Atypical Antipsychotics in Japan: A Retrospective Observational Study
por: Hishimoto, Akitoyo, et al.
Publicado: (2022)

PS151. Adjunctive brexpiprazole (OPC-34712) in patients with major depressive disorder and anxiety symptoms: an exploratory study
por: Davis, Lori, et al.
Publicado: (2016)

Adjunctive brexpiprazole for elderly patients with major depressive disorder: An open‐label, long‐term safety and tolerability study
por: Lepola, Ulla, et al.
Publicado: (2018)

Discovery research and development history of the dopamine D(2) receptor partial agonists, aripiprazole and brexpiprazole
por: Kikuchi, Tetsuro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vhalgu5errmbo5s2g5q78jh57e